Regional and Country Priorities for vaccine research

Angela Hwang
Published: 2022-10-24 | Updated: 2025-07-08

A new mechanism is being established under Immunization Agenda 2030 (IA2030) to identify regional and country priorities for vaccine research and development (R&D). These priorities will inform Monitoring and Evaluation (M&E) for IA2030. They will also be disseminated widely to enable greater coordination among funders, researchers, vaccine developers, vaccine implementers, and other stakeholders.

The first question being addressed is What are regional and country priorities for new vaccine product R&D for endemic pathogens? Once established, this mechanism can be used for additional questions of interest to regional and global stakeholders.

For more information, email This email address is being protected from spambots. You need JavaScript enabled to view it..

Context and results

TitleAuthorYearTypeLanguage
Partnering with regions and countries to identify priority pathogens for vaccines, October 2022Vaccine Prioritization & Platforms Team2022PresentationEnglish
Partnering with regions and countries to identify priority pathogens for vaccines, December 2023Vaccine Prioritization & Platforms Team2023PresentationEnglish
Identifying WHO global priority endemic pathogens for vaccine research and development (R&D) using multi-criteria decision analysis (MCDA): an objective of the Immunization Agenda 2030Mateusz Hasso-Agopsowicz, Angela Hwang, Maria-Graciela Hollm Delgado, Isis Umbelino-Walker, Ruth A. Karron, Raman Rao, Kwaku Poku Asante, Meru Sheel, Erin Grace Sparrow, Birgitte K. Giersing2024Journal articleEnglish

Methods